Memantine ER 28 mg is an extended-release formulation of memantine, a medication used to treat moderate to severe Alzheimer's disease [1]. It is designed to release the active ingredient gradually over a 24-hour period, allowing for once-daily dosing [2].
How does memantine ER 28 mg work?
Memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist [1]. In Alzheimer's disease, overstimulation of NMDA receptors by glutamate is thought to contribute to nerve cell damage [3]. Memantine works by blocking excessive glutamate activity, which may help to improve cognitive function and slow the progression of symptoms [1][3].
What is the difference between immediate-release and extended-release memantine?
Immediate-release (IR) memantine requires dosing multiple times a day, typically twice daily [4]. Extended-release (ER) formulations, like memantine ER 28 mg, are designed for once-daily administration [2]. This can improve patient adherence and convenience. The ER formulation also aims to provide more stable drug concentrations in the bloodstream throughout the day compared to IR formulations [5].
When does memantine's patent expire?
The patent expiry for memantine and its formulations can be complex, involving multiple patents covering the active ingredient, manufacturing processes, and specific formulations. Information on the patent status of memantine formulations is available through resources like DrugPatentWatch.com [6]. Generally, patents for older drugs like memantine have expired or are nearing expiration, opening the door for generic versions.
Can generic memantine ER 28 mg be available?
Once primary patents and any associated market exclusivities expire, generic manufacturers can seek approval to market their versions of memantine ER 28 mg [6]. The availability of generic options can lead to lower drug costs.
What are the common side effects of memantine ER?
Common side effects associated with memantine, including the ER formulation, can include dizziness, headache, confusion, constipation, and somnolence [1]. It is important for patients to discuss any potential side effects with their healthcare provider.
How is memantine ER 28 mg typically prescribed?
Memantine ER 28 mg is usually prescribed as a starting dose and then titrated up to the target dose over a period of time [5]. Dosing should always be determined and managed by a qualified healthcare professional based on individual patient needs and tolerance.
What clinical data supports memantine ER 28 mg?
Clinical trials have demonstrated that memantine ER can improve cognitive function and global status in patients with moderate to severe Alzheimer's disease [5]. These studies typically compare the drug to a placebo and assess various cognitive and functional measures.
Sources:
[1] https://www.nami.org/About-Mental-Illness/Treatments/Mental-Health-Medications/Memantine
[2] https://www.webmd.com/drugs/drug-70000/memantine-extended-release-oral-capsule
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2891026/
[4] https://www.mayoclinic.org/drugs-supplements/memantine-oral-capsule-oral-tablet-long-acting-oral-capsule-oral-tablet-extended-release/medical-history/drg-20073500
[5] https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021701lbl.pdf
[6] https://drugpatentwatch.com/